Skip to main content
Figure 2 | Journal of Biomedical Science

Figure 2

From: Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia

Figure 2

Outcome of patients with CN-AML according to BDH2 expression levels and FLT3- ITD mutation status. In 85 patients receiving intensive induction chemotherapy, we analyzed A) overall survival; B) leukemia-free survival between 2 different BDH2 expression groups; and C) overall survival; D) leukemia-free survival between groups differentiated by BDH2 expression level, combined with the FLT3-ITD mutation status.

Back to article page

Journal of Biomedical Science

ISSN: 1423-0127